Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06848075 · ClinicalTrials.gov registry record · Phase 2
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
A Phase 2 study, sponsored by Kallyope.
- Completed
- Registry status
- Phase 2
- Development phase
- 431
- Enrollment target
NCT06848075: Completed Phase 2 study, sponsored by Kallyope.
NCT06848075 is a Phase 2 study that has completed, run by Kallyope. The registered enrollment target is 431 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (224% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06848075, a Phase 2 study, has completed, sponsored by Kallyope.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 431 participants
- Enrollment target
Study Summary
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the treatment of moderate or severe migraine.
Primary Outcome
Assessed using the number of evaluable participants that reported no pain at 2 hours post-dose. Pain was measured on a 4-point Likert scale (0 = none, 1 = mild, 2 = moderate, 3 = severe)
Interventions
- DRUG Placebo
- DRUG Elismetrep (K-304) Dose Level 1
- DRUG Elismetrep (K-304) Dose level 2
- DRUG Elismetrep (K-304) Dose level 3
- DRUG Elismetrep (K-304) Dose level 4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 431 participants |
| Start Date | 2025-03-05 |
| Est. Completion | 2025-08-11 |
| Phase | Phase 2 |
What the finished NCT06848075 record still lists
NCT06848075 is an interventional study that assigns participants to a tested intervention. The registered 431 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (224% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT06848075 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06848075 about?
NCT06848075 is a clinical study titled "A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine". This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the treatment of moderate or severe migraine.
What is the current status of trial NCT06848075?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 431 participants. The study started on 2025-03-05. Estimated completion is 2025-08-11.
What interventions are being tested in trial NCT06848075?
The interventions under investigation include: Placebo (DRUG), Elismetrep (K-304) Dose Level 1 (DRUG), Elismetrep (K-304) Dose level 2 (DRUG), Elismetrep (K-304) Dose level 3 (DRUG), Elismetrep (K-304) Dose level 4 (DRUG).
Who is sponsoring clinical trial NCT06848075?
This trial is sponsored by Kallyope, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06848075's enrollment target sits among peer trials
431 90th of 2000 higher than 1,911 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05128890 · 431 participants
Evaluation of Resection Techniques for Pancreatic Tumors
- NCT05271240 · 432 participants · Phase 3
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
- NCT05365815 · 432 participants · NA
Melanated Group Midwifery Care (MGMC)
- NCT05499507 · 432 participants · NA
The Path to Optimal Black Maternal Heart Health: Comparing Two CVD Risk Reduction Interventions (Change of HEART)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI